EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

CRISPR/Cas13d targeting suppresses repeat-associated non-AUG translation of C9orf72 hexanucleotide repeat RNA

Honghe Liu, Xiao-Feng Zhao, Yu-Ning Lu, Lindsey R Hayes, Jiou Wang

Journal of Clinical Investigation · 2024

DOI: 10.1172/jci179016 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Clinical Investigation, 2024. Verfasst von Honghe Liu und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biochemistry and Molecular Biology, Bloomberg School of Public Health, and. Hauptthemen laut MEDLINE: C9orf72 Protein, Amyotrophic Lateral Sclerosis, CRISPR-Cas Systems, Frontotemporal Dementia. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 55 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NINDS NIH HHS, NIH, Walder Foundation, Packard Center for ALS Research at Johns Hopkins.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

A hexanucleotide GGGGCC repeat expansion in the non-coding region of the C9orf72 gene is the most common genetic mutation identified in patients with amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). The resulting repeat RNA and dipeptide repeat proteins from non-conventional repeat translation have been recognized as important markers associated with the diseases. CRISPR/Cas13d, a powerful RNA-targeting tool, has faced challenges in effectively targeting RNA with stable secondary structures. Here we report that CRISPR/Cas13d can be optimized to specifically target GGGGCC repeat RNA. Our results demonstrate that the CRISPR/Cas13d system can be harnessed to significantly diminish the translation of poly-dipeptides originating from the GGGGCC repeat RNA. This efficacy has been validated in various cell types, including induced pluripotent stem cells and differentiated motor neurons originating from C9orf72-ALS patients, as well as in C9orf72 repeat transgenic mice. These findings demonstrate the application of CRISPR/Cas13d in targeting RNA with intricate higher-order structures and suggest a potential therapeutic approach for ALS and FTD.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

C9orf72 ProteinAmyotrophic Lateral SclerosisCRISPR-Cas SystemsFrontotemporal DementiaDNA Repeat ExpansionMice, TransgenicHumansAnimalsMiceProtein BiosynthesisInduced Pluripotent Stem CellsRNAMotor Neurons

Stichwörter der Autor:innen

Gene therapyGeneticsMolecular biologyNeurodegenerationNeuroscience

Substanzen

C9orf72 ProteinC9orf72 protein, humanRNAC9orf72 protein, mouse

Autor:innen und Institutionen

  • Department of Biochemistry and Molecular Biology, Bloomberg School of Public Health, and.
  • Department of Neuroscience, School of Medicine, Johns Hopkins University, Baltimore, Maryland, USA.
  • Brain Science Institute and Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.

Förderung

  • NINDS NIH HHS
  • NIH, Walder Foundation, Packard Center for ALS Research at Johns Hopkins

Zitieren

APA

Liu, H., Zhao, X. F., Lu, Y. N., Hayes, L. R., & Wang, J. (2024). CRISPR/Cas13d targeting suppresses repeat-associated non-AUG translation of C9orf72 hexanucleotide repeat RNA. Journal of Clinical Investigation. https://doi.org/10.1172/jci179016

Vancouver

Liu H, Zhao XF, Lu YN, Hayes LR, Wang J. CRISPR/Cas13d targeting suppresses repeat-associated non-AUG translation of C9orf72 hexanucleotide repeat RNA. Journal of Clinical Investigation. 2024. doi:10.1172/jci179016

BibTeX
@article{Liu2024,
  author = {Liu, Honghe and Zhao, Xiao-Feng and Lu, Yu-Ning and Hayes, Lindsey R and Wang, Jiou},
  title = {CRISPR/Cas13d targeting suppresses repeat-associated non-AUG translation of C9orf72 hexanucleotide repeat RNA},
  journal = {Journal of Clinical Investigation},
  year = {2024},
  doi = {10.1172/jci179016}
}
Kostenlos starten →